Day’s Recap is unavailable for this topic and date. Feel free to go through our curated list of stories below.
Other Developments
A curated list of other prominent stories from this day.
9:59 PMScienceDaily
Millions take calcium and vitamin D for bone health. A major review finds little benefit
Summary
A review of more than 153,000 adults found that calcium and vitamin D supplements, taken alone or together, did little to prevent fractures or falls in most older people. The researchers said prevention efforts should focus more on balance and resistance exercise.
The evidence weakens the case for routine calcium and vitamin D supplementation among older adults
Unlock the full First Pass Analysis to get a better understanding of why this story matters
Why it matters
Millions of older adults may be taking supplements that offer little preventive benefit outside specific medical needs.
'Epigenetic' editing is here: gene-tagging technique banishes hepatitis B virus
Summary
Researchers used chemical tags to silence hepatitis B DNA embedded in infected cells, targeting the viral reservoir that current treatments often suppress but do not remove. The approach represents an epigenetic strategy rather than a permanent change to the underlying genetic code.
The decisive shift is the ability to shut down persistent viral DNA at its hiding
Unlock the full First Pass Analysis to get a better understanding of why this story matters
Why it matters
A way to silence hepatitis B's genomic reservoir could reduce lifelong treatment and prevent the liver damage caused by chronic infection.
STAT+: Radiopharma companies merge after one receives surprise FDA rejection
Summary
ITM Isotope Technologies Munich and Telix Pharmaceuticals, two prominent radiopharmaceutical companies, are merging after one of the businesses received an unexpected FDA rejection.
The FDA setback has helped trigger consolidation in a fast-growing but regulatory-sensitive field. The merger
Unlock the full First Pass Analysis to get a better understanding of why this story matters
Why it matters
The deal shows how a single regulatory blow can accelerate consolidation in an emerging healthcare market.
Ex-Banker Eyeing Top WHO Job Says Agency Can Tap Outside Money
Summary
Indonesia’s Health Minister Budi Gunadi Sadikin, a candidate to lead the World Health Organization, says the agency should seek funding beyond its existing budget to support its own operations and member countries.
Sadikin is proposing a broader financing model as the WHO faces pressure to expand its
Unlock the full First Pass Analysis to get a better understanding of why this story matters
Why it matters
The next WHO leader may need to redesign how the agency funds global health work while limiting dependence on powerful external donors.
8 common food additives linked to high blood pressure and heart disease
Summary
An observational study linked higher consumption of eight widely used preservatives in processed foods with increased rates of hypertension and cardiovascular disease. The findings show an association, not proof that the additives directly caused the health problems.
The key shift is that everyday exposure to multiple preservatives may track with cardiovascular risk,
Unlock the full First Pass Analysis to get a better understanding of why this story matters
Why it matters
If confirmed, the findings could reshape processed-food regulation and give consumers another reason to reduce reliance on packaged foods.
Investors are pressing Novo Nordisk to diversify its growth strategy and pursue acquisitions and new medicines as the Ozempic maker prepares for a shareholder meeting. The demands reflect concern that the company cannot rely indefinitely on its current blockbuster portfolio.
Investor pressure is shifting from maximizing the existing obesity and diabetes franchise to proving that
Unlock the full First Pass Analysis to get a better understanding of why this story matters
Why it matters
Novo's response will signal whether it can turn blockbuster cash flow into a durable drug pipeline before growth slows or concentration becomes a bigger risk.